Ergothioneine: The Longevity-Vitamin Hypothesis

In 2018 the biochemist Bruce Ames proposed a new category of nutrient he called a "longevity vitamin" — a compound that is not required to prevent an acute deficiency disease, and so has never been given a formal Recommended Dietary Allowance, but that may quietly protect long-term health and reduce the diseases of aging. Ergothioneine is the poster child for that idea, championed in particular by the mushroom scientist Robert Beelman. The case rests on three unusual facts: the body cannot make ergothioneine, it maintains a dedicated transporter to hoard it from the diet, and it holds onto it for weeks. This page lays out the argument in full — and, just as importantly, explains why it is still a hypothesis. The human evidence so far is almost entirely association-level: it shows that people with more ergothioneine tend to be healthier, not yet that giving people more ergothioneine makes them healthier.

What "Longevity Vitamin" Means
Humans Cannot Make It — Only Fungi and Some Bacteria Can
The Dedicated Transporter (OCTN1 / SLC22A4)
Tissue Accumulation and Long Retention
Beelman's Dietary-Decline Argument
What the Human Association Studies Show
The Honest Caveat: Association, Not Proven Cause
Is It Really a Vitamin? A Semantic and Scientific Question
Practical Takeaways
Key Research Papers
Connections
Featured Videos

What "Longevity Vitamin" Means

The classical vitamins were discovered by finding a deficiency disease and then the compound that cured it: no vitamin C, and you get scurvy; no vitamin D, and children get rickets. This "acute deficiency" model defined the whole field and set the Recommended Dietary Allowances. Bruce Ames, in a 2018 paper in the Proceedings of the National Academy of Sciences, argued that this model is incomplete. He proposed that some nutrients do not cause a dramatic short-term deficiency disease when they run low, but instead cause a slow, silent increase in the risk of cancer, cardiovascular disease, cognitive decline, and other conditions of aging over decades.

Ames reasoned from what he called the "triage theory": when a nutrient is scarce, the body prioritizes the functions needed for immediate survival and reproduction, and quietly under-invests in the repair and maintenance functions that only matter over the long run. A modest shortfall therefore produces no obvious symptom — but it accelerates aging. He grouped roughly 30 compounds, ergothioneine among them, into this proposed "longevity vitamin and protein" category. The label is a hypothesis-generating idea, not a regulatory designation; ergothioneine is not officially recognized as a vitamin by any government body.

Back to Table of Contents

Humans Cannot Make It — Only Fungi and Some Bacteria Can

The first requirement for anything to be considered vitamin-like is that the body cannot synthesize it and must obtain it from outside. Ergothioneine clears this bar cleanly. The biosynthetic pathway that builds ergothioneine from the amino acid histidine exists only in certain fungi — including every edible mushroom — and in some bacteria such as mycobacteria and cyanobacteria. Plants and animals lack the enzymes entirely.

This means the ergothioneine in a steak, a kidney bean, or your own bloodstream did not originate in the animal or plant. It was made by fungi somewhere earlier in the food chain: by mushrooms directly, or by soil fungi whose ergothioneine was taken up by plant roots, or by the gut and dietary fungi consumed by the animal. Humans sit at the far end of that chain, entirely dependent on dietary intake — exactly as we are for vitamin C or the B vitamins. Unlike glutathione, which the body manufactures continuously from cysteine, glutamate, and glycine, ergothioneine cannot be replaced by internal production if the diet is short.

Back to Table of Contents

The Dedicated Transporter (OCTN1 / SLC22A4)

The single most persuasive piece of evidence that ergothioneine matters to human biology is that we have a protein whose main job appears to be capturing it. In 2005, Dirk Gründemann and colleagues reported in PNAS that the transporter previously known as OCTN1 — the product of the gene SLC22A4 — is in fact a high-affinity, highly specific carrier for ergothioneine. They found that OCTN1 transports ergothioneine roughly a hundred times more efficiently than the other molecules it had been assumed to carry.

The logic here is evolutionary. Building and maintaining a dedicated transporter is metabolically expensive. Natural selection does not preserve such machinery across hundreds of millions of years of vertebrate evolution unless the cargo does something useful. As Gründemann put it in a follow-up review, the transporter both controls ergothioneine activity (by determining which cells get it) and indicates it (its presence flags cells that need ergothioneine).

Where OCTN1 sits is itself revealing. It is concentrated in tissues under heavy oxidative load: red blood cells and their precursors in bone marrow, the liver, the kidney, the lens and cornea of the eye, the lining of the gut (where it absorbs dietary ergothioneine), and, importantly, the brain. Cells appear to install OCTN1 precisely where they anticipate needing antioxidant protection. Some studies also show that OCTN1 expression is upregulated under oxidative stress — the cell reaches for more ergothioneine when it is under attack.

A footnote of genetic interest: variants in SLC22A4 have been studied in relation to autoimmune and inflammatory conditions such as rheumatoid arthritis and Crohn's disease. The relationships are complex and not the point of this page, but they underline that this transporter is biologically consequential rather than vestigial.

Back to Table of Contents

Tissue Accumulation and Long Retention

Most antioxidants are short-lived. Vitamin C is cleared within hours; glutathione is constantly synthesized and consumed. Ergothioneine behaves the opposite way. Once absorbed, it is distributed by OCTN1 into tissues and held there for a remarkably long time — studies in animals and humans indicate a biological half-life measured in weeks, not hours.

Tang, Cheah, Yew, and Halliwell traced dietary ergothioneine through mouse tissues in a 2018 Scientific Reports study and found it accumulated preferentially in the tissues expressing OCTN1, with slow turnover and evidence that it was being retained rather than simply excreted. In humans, the 2017 study by Cheah and colleagues that gave purified ergothioneine to healthy volunteers found that blood levels rose and then declined only gradually over the following weeks, with relatively little appearing in urine — the body was keeping most of what it absorbed.

This retention is a direct consequence of the molecule's chemistry. Ergothioneine exists predominantly as a stable thione (a sulfur double-bonded to carbon) rather than a reactive thiol (an –SH group). Thiols like those in cysteine and glutathione readily auto-oxidize and get used up; the thione form does not, so ergothioneine can sit in a cell as a reserve, drawn upon only when reactive species appear. The antioxidant and mitochondria page explores this chemistry in detail.

Back to Table of Contents

Beelman's Dietary-Decline Argument

Robert Beelman, a food scientist at Penn State who spent decades studying mushrooms, is the researcher most associated with applying the "longevity vitamin" label specifically to ergothioneine. In a 2020 paper in the Journal of Nutritional Science titled "Is ergothioneine a ‘longevity vitamin’ limited in the American diet?", Beelman and colleagues laid out an ecological argument.

Their reasoning runs like this. Because mushrooms are overwhelmingly the richest dietary source, national ergothioneine intake tracks mushroom consumption. Americans eat relatively few mushrooms, and Beelman estimated average U.S. intake at only around 1–1.5 mg per day — far below intake in countries such as Italy or France where mushroom-rich cuisines are common. He then noted that countries with lower estimated ergothioneine intake tend to have higher rates of neurodegenerative disease, and proposed that dietary ergothioneine deficiency might be one under-appreciated contributor.

It is essential to read this argument for exactly what it is: an ecological correlation used to generate a hypothesis, not to prove one. Cross-country comparisons of diet and disease are riddled with confounders — wealth, healthcare access, other dietary differences, life expectancy, and diagnostic practices all vary alongside mushroom consumption. Beelman himself framed it as a call for research, not a settled conclusion. The value of the argument is that it is testable, and it has motivated the human cohort studies and early trials described on the brain and aging page.

Back to Table of Contents

What the Human Association Studies Show

The strongest human data come from large metabolomics cohorts, which measure hundreds of blood compounds at once and then follow people for years to see who develops disease. The standout result is from Smith and colleagues, published in the journal Heart in 2020. Working with the Swedish Malmö Diet and Cancer study, they found that people with higher blood ergothioneine at baseline had a significantly lower risk of dying — from cardiovascular causes and from all causes — over roughly two decades of follow-up. Higher ergothioneine also tracked with a healthier diet pattern rich in vegetables, fruit, fish, and, unsurprisingly, mushrooms.

This is a striking and much-cited finding, and it is genuinely suggestive. But the authors were careful, and so should we be: an observational association cannot separate whether ergothioneine itself protected these people, or whether ergothioneine is simply a faithful marker of an overall healthy diet and body that protected them for many other reasons. That distinction is the whole ballgame, and it gets its own section next.

Back to Table of Contents

The Honest Caveat: Association, Not Proven Cause

Every serious review of ergothioneine — including those by its most enthusiastic investigators, Barry Halliwell and Irwin Cheah — states plainly that the case for a health benefit in humans remains unproven. The reasons are worth spelling out, because they are the same reasons that trip up nutrition science generally:

Reverse causation. Illness and inflammation can lower blood ergothioneine (partly by changing OCTN1 activity and diet). So low ergothioneine might be a consequence of poor health rather than a cause of it.
Confounding by diet. People who eat mushrooms tend to eat more vegetables and fish and to have healthier lifestyles overall. Ergothioneine may be an innocent bystander — a biomarker of a good diet, not the active ingredient.
Marker versus mechanism. A compound can be an excellent predictor of health without being causally responsible for it, the way a low resting heart rate predicts fitness without itself creating it.

The only way to resolve this is a randomized controlled trial: give one group ergothioneine and another a placebo, and see whether outcomes differ. Those trials are only now beginning — the first, a small study in people with mild cognitive impairment (Yau and colleagues, 2024), is discussed on the brain and aging page. Until such trials report robust clinical endpoints, the honest verdict is: promising, biologically plausible, well worth studying — and not proven.

Back to Table of Contents

Is It Really a Vitamin? A Semantic and Scientific Question

Strictly speaking, "vitamin" is reserved for compounds whose deficiency causes a defined disease. By that classical standard, ergothioneine does not qualify: no one has demonstrated an "ergothioneine deficiency disease" with clear symptoms that resolve on repletion. That is precisely why Ames coined the softer term "longevity vitamin" — to name a category that sits between essential vitamins and optional nutraceuticals.

Some researchers prefer the phrase "conditionally essential" or, as Bindu Paul titled a 2022 review, a "stress vitamin." The common thread is a nutrient the body clearly values (hence the transporter and the retention) but that has no established acute requirement. Whether ergothioneine eventually earns full vitamin status will depend on the trial evidence. For now, the most accurate way to describe it is: a diet-derived, transporter-hoarded antioxidant with vitamin-like behavior and an unproven but plausible long-term health role.

Back to Table of Contents

Practical Takeaways

It costs little to raise your intake. Because mushrooms are so much richer than any other food, a couple of servings of mushrooms per week meaningfully increases ergothioneine intake. See the food sources page for which mushrooms are richest.
It is safe. No toxicity has been reported at dietary levels or in the supplement trials conducted so far; the body simply retains what it needs and the molecule is chemically stable.
Do not treat it as a cure. The evidence supports ergothioneine as part of a mushroom-inclusive, vegetable-rich diet — not as a stand-alone remedy for any disease.
Watch the trials. The interesting question over the next several years is whether randomized supplementation trials confirm the cohort associations. Until then, enjoy mushrooms for their many established merits and treat the longevity-vitamin idea as a promising work in progress.

Back to Table of Contents

Key Research Papers

Ames BN (2018). Prolonging healthy aging: Longevity vitamins and proteins. PNAS 115(43):10836–10844. — PubMed 30322941
Beelman RB, Kalaras MD, Phillips AT, Richie JP Jr (2020). Is ergothioneine a ‘longevity vitamin’ limited in the American diet? Journal of Nutritional Science 9:e52. — PubMed 33244403
Gründemann D et al. (2005). Discovery of the ergothioneine transporter. PNAS 102(14):5256–5261. — PubMed 15795384
Gründemann D (2012). The ergothioneine transporter controls and indicates ergothioneine activity — a review. Preventive Medicine 54 Suppl:S71–S74. — PubMed 22182480
Tang RMY, Cheah IK, Yew TSK, Halliwell B (2018). Distribution and accumulation of dietary ergothioneine and its metabolites in mouse tissues. Scientific Reports 8:1601. — PubMed 29371632
Smith E et al. (2020). Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart 106(9):691–697. — PubMed 31672783
Paul BD (2022). Ergothioneine: A Stress Vitamin with Antiaging, Vascular, and Neuroprotective Roles? Antioxidants & Redox Signaling 36(16–18):1306–1317. — PubMed 34619979
Cheah IK, Halliwell B (2012). Ergothioneine; antioxidant potential, physiological function and role in disease. Biochimica et Biophysica Acta 1822(5):784–793. — PubMed 22001064
Borodina I et al. (2020). The biology of ergothioneine, an antioxidant nutraceutical. Nutrition Research Reviews 33(2):190–217. — PubMed 32051057
May-Zhang LS et al. (2025). Ergothioneine for cognitive health, longevity and healthy ageing: where are we now? Proceedings of the Nutrition Society. — PubMed 40968729